Author name: Sreenivasulu Malkari

Blog

MAS Financial Q2 Results: Axis Securities Reiterates ‘Buy’ Call, Expects Strong Growth

MAS Financial Q2 Review: Strong Growth Prospects Ahead MAS Financial Services Ltd. has reported its Q2 results, and Axis Securities has reiterated its ‘Buy’ call on the stock. The brokerage firm expects strong growth prospects for the company, driven by a robust distribution network and adequate capitalization. The stock currently trades at 1.7x FY27E BV, […]

Blog

Motilal Oswal Downgrades Updater Services To ‘Neutral’ Amid Guidance Cuts, Near-Term Headwinds

Motilal Oswal Downgrades Updater Services To ‘Neutral’ Amid Guidance Cuts, Near-Term Headwinds Updater Services Ltd. recently reported its Q2 FY26 results, which fell short of expectations. The company’s revenue grew 7% year-over-year (YoY) to Rs 7.3 billion, below the estimated Rs 7.7 billion. The core Ebitda margin came in at 4.3%, down 130 basis points

Blog

India and China: A Tale of Two Markets with Different Fundamentals

Introduction to the Indian and Chinese Markets The Indian and Chinese stock markets have been making headlines in recent times, with China experiencing a resurgence in its stock market, while India has been underperforming. According to Mark Matthews, Head of Research Asia at Julius Baer, these two markets are driven by different fundamentals and opportunities,

Blog

Lenskart IPO: Ambit Gives Sell Rating, Cites Valuation Concerns

Lenskart IPO: Ambit Gives Sell Rating, Cites Valuation Concerns Lenskart, the popular eyewear retailer, is set to list on the Indian stock markets on Monday, but has already received its first sell rating from Ambit, a leading brokerage firm. The rating comes as a surprise, given Lenskart’s strong brand and growth prospects. However, Ambit believes

Blog

Indoco Remedies Q2 Review: Dolat Capital Revises Target Price, Maintains ‘Sell’ Rating

Indoco Remedies Q2 Review: A Mixed Bag for Investors Indoco Remedies Ltd., a leading Indian pharmaceutical company, recently announced its Q2 FY26 earnings, which came in above estimates. However, despite the positive earnings surprise, Dolat Capital has downgraded its Ebitda estimates and maintained a ‘Sell’ rating with a revised target price of Rs 224. Q2

Scroll to Top